MacroGenics Inc. (NASDAQ:MGNX) was up 2.2% on Friday . The company traded as high as $27.15 and last traded at $27.04, with a volume of 153,280 shares trading hands. The stock had previously closed at $26.46.

A number of equities research analysts have weighed in on MGNX shares. Morgan Stanley lifted their price target on shares of MacroGenics from $20.00 to $21.00 in a research report on Friday, April 8th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of MacroGenics in a research report on Tuesday, June 14th. BTIG Research reiterated a “buy” rating and set a $35.00 price target on shares of MacroGenics in a research report on Sunday, May 22nd. Zacks Investment Research upgraded shares of MacroGenics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Leerink Swann restated an “outperform” rating and issued a $47.00 price objective on shares of MacroGenics in a report on Thursday, May 19th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $40.25.

The stock’s market capitalization is $941.01 million. The stock has a 50-day moving average price of $26.10 and a 200 day moving average price of $21.49.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.21. Analysts forecast that MacroGenics Inc. will post ($2.29) EPS for the current fiscal year.

In other news, CMO Jon Marc Wigginton sold 5,000 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total transaction of $136,100.00. Following the transaction, the chief marketing officer now directly owns 5,000 shares in the company, valued at approximately $136,100. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Lynn Cilinski sold 8,922 shares of the stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $27.22, for a total transaction of $242,856.84. Following the transaction, the vice president now owns 10,845 shares in the company, valued at $295,200.90. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in the company. Cornerstone Capital Management Holdings LLC. raised its position in shares of MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 20,929 shares during the last quarter. California State Teachers Retirement System raised its position in shares of MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,809,000 after buying an additional 1,038 shares during the last quarter. GAM Holding AG raised its position in shares of MacroGenics by 118.3% in the fourth quarter. GAM Holding AG now owns 63,100 shares of the biopharmaceutical company’s stock valued at $1,954,000 after buying an additional 34,200 shares during the last quarter. Marshall Wace LLP raised its position in shares of MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the last quarter.

MacroGenics, Inc is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.